HomeMy WebLinkAbout20250024.tiff Resolution
Approve Cooperation Agreement for Payment of Opioid Settlement Funds for
Substance Abuse Prevention and Authorize Chair to Sign—Weld Opioid Regional
Council
Whereas,the Board of County Commissioners of Weld County,Colorado,pursuant to
Colorado statute and the Weld County Home Rule Charter,is vested with the authority of
administering the affairs of Weld County,Colorado,and
Whereas,the Board has been presented with a Cooperation Agreement for the Payment
of Opioid Settlement Funds for Substance Abuse Prevention between the County of
Weld,State of Colorado,by and through the Board of County Commissioners of Weld
County,on behalf of the Department of Public Health and Environment,and the Weld
Opioid Regional Council,commencing January 1,2025,and ending December 31,2025,
with further terms and conditions being as stated in said agreement,and
Whereas,after review,the Board deems it advisable to approve said agreement,a copy
of which is attached hereto and incorporated herein by reference.
Now,therefore,be it resolved by the Board of County Commissioners of Weld County,
Colorado,that the Cooperation Agreement for the Payment of Opioid Settlement Funds
for Substance Abuse Prevention between the County of Weld,State of Colorado,by and
through the Board of County Commissioners of Weld County,on behalf of the Department
of Public Health and Environment,and the Weld Opioid Regional Council,be,and hereby
is,approved.
Be it further resolved by the Board that the Chair be,and hereby is,authorized to sign
said agreement.
The Board of County Commissioners of Weld County,Colorado,adopted the above
and foregoing Resolution,on motion duly made and seconded,by the following vote on
the 6th day of January,A.D.,2025,nunc pro tunc January 1,2025:
Perry L.Buck,Chair:Aye �,•�-�,
Scott K.James,Pro-Tem:Aye
Jason S.Maxey:Aye A:
Lynette Peppler:Aye '�.'��'_ ��
Kevin D.Ross:Aye
Approved as to Form: ,• .•
Bruce Barker,County Attorney
Attest:
Esther E.Gesick,Clerk to the Board
cc;FtL-(sc ter/gN),cA(t3t3/10-t) 2025-0024
O1/aq/25 HL0058
BOARD OF COUNTY COMMISSIONERS
PASS-AROUND REVIEW
PASS-AROUND TITLE:WCDPHE Opioid Council Cooperative Agreement
DEPARTMENT: Public Health,Health Education and Communication DATE: 12/17/2024
PERSON REQUESTING: Jason Chessher,Executive Director
Bob McDonald,Health Education,Communication and Planning Division Director
Brief description of the problem/issue:
The Health Education,Communication,and Planning Division(HECP)coordinates and facilitates the Weld
Regional Opioid Abatement Council(WROC)meetings.We have requested funding($99,000.00 for salary and
benefits)from the Council to support an FTE to serve as a coordinator and liaison to all funded entities and to
coordinate outreach related to substance abuse.Funds are to be provided by the WROC.This position not
only schedules meetings and records minutes but provides support to funded agencies throughout the year,
including evaluation services, reporting, and budget monitoring.This Cooperative Agreement is between
WCDPHE and the WROC to outline the funding request for 2025.
The remainder of the funding received from the WROC($13,000.00 total)will be used by the HECP Division to
purchase and distribute naloxone(Narcan-$10,000.00)to the community and provide additional support
($3000.00)for substance use disorder prevention related materials.
What options exist for the Board?Approve or deny
Consequences:
- Approving and signing this cooperation agreement will enable the Department of Health to continue
to support the WROC;additionally,approval will ensure that nearly 200 units of naloxone(estimated)
can be distributed to prevent fatal opioid overdoses in Weld County.
- Declining this agreement will result in the loss of$99,000.00 that pays for.9 FTE as well as limiting
the county's ability to distribute naloxone and implement prevention programming.
Impacts:
- The WROC would be left without a support person and representative to attend the state Opioid
Council meetings.Funded agencies may misuse funds,deviate from council approved plans,and fail
to submit required documentation.Reducing the availability of naloxone may increase the likelihood
of fatal opioid overdoses in the community.
Costs(Current Fiscal Year/Ongoing or Subsequent Fiscal Years):This agreement will grant
$112,000.00 to HECP for the period of January 1,2025 through December 31,2025.
Recommendation:I recommend approval to place this cooperation agreement on a future BOCC agenda for
formal consideration.
2025-0024
1 AC H L00513
Support Recommendation Schedule
Place on BOCC Agenda Work Session Other/Comments:
Perry L.Buck,Pro-Tem 631-727
Mike Freeman
Scott K.James
Kevin D.Ross,Chair
Lori Saine
COOPERATION AGREEMENT FOR PAYMENT OF OPIOID SETTEMENT FUNDS
THIS COOPERATION AGREEMENT is made and entered into effective as of the date set forth
below,between the WELD OPIOID REGIONAL COUNCIL,a Regional Council created by and through
the agreements mentioned below for the purposes set forth therein,whose address is 1555 N 17.Avenue
Greeley,CO 80631,hereinafter referred to as"Regional Council,"and Weld County Department of
Public Health and Environment,whose address is 1555 N 17.Avenue Greeley,Colorado 80631
hereinafter referred to as"Recipient."
WITNESSETH:
WHEREAS,the Regional Council oversees the procedures by which the Weld Region may request
Opioid Funds from the Colorado Opioid Abatement Council(COAC)and the procedures by which the
allocation of the Weld Region's Share of Opioid Funds(the"Allocation")are administered,and
WHEREAS,the Regional Council has made the following Allocation to Recipient,as detailed in
the"Weld Region 3 Opioid Council—Funding Distribution,"for the current year:$112,000.00 for the
Approved Purpose(s)detailed in Exhibit E,Statement of Work(the"Distribution"),and in accordance with
the annual budget that is developed,submitted and approved by the Opioid Regional Council and COAC,
and
WHEREAS,this Cooperation Agreement details the timing of the Distribution,and the
terms and conditions the Recipient must meet to receive the Distribution,and WHEREAS,the Recipient
agrees to comply with the terms and conditions of the Distribution detailed herein.
WITNESSETH:
NOW,THEREFORE,in consideration of the mutual promises and covenants contained herein,the
parties hereto agree as follows:
1.Distribution of Allocation by the Regional Council.The Regional Council will release and
disburse settlement funds bi-annually(e.g.March and September);and,at a timeline that is established by
the Council.A one-time funding disbursement option may also be available(e.g.for organizations who
simply need a"one-time purchase"of equipment or service).The Distribution is made pursuant to the
following terms and conditions:
a.The Distribution is an"Approved Purpose,"as defined in paragraph A.1.of the Colorado Opioids
Settlement Memorandum of Understanding,dated August 26,2021,and as further detailed in
Exhibit"E-List of Opioid Remediation Uses"attached thereto.Recipient agrees not to spend any
part of the Distribution on anything other than the Approved Purpose described above.
b.The Recipient shall report to the Regional Council all expenditures of the Distribution on forms
or in the manner directed by the Regional Council.
2.Term.The term of this COOPERATION AGREEMENT shall be from January 1,2025 to
December 31,2025.The COOPERATION AGREEMENT may be terminated if,after notice of breach by
the Regional Council to the Recipient,such breach is not cured by the Recipient within ten(10)calendar
days after the Recipient's receipt of notice.Upon such termination,any part of the Distribution then unspent
shall be returned forthwith by the Recipient to the Regional Council.
1
3.Promise by the Recipient to Comply with Terms and Conditions of Distribution.The Recipient
promises to strictly comply with the terms and conditions of the Distribution set forth in Paragraphs l.a.
and 1.b.,above.Noncompliance with such terms and condition may result in termination of this
COOPERATION AGREEMENT and return to the Regional Council of any unspent portion of the
Distribution to the Regional Council.
4.Entire Agreement.This writing constitutes the entire agreement between the parties hereto with
respect to the subject matter herein,and shall be binding upon said parties,their officers,employees,agents
and assigns and shall inure to the benefit of the respective survivors,heirs,personal representatives,
successors and assigns of said parties.
5.No Waiver of Immunity.No portion of this Cooperation Agreement shall be deemed to constitute
a waiver of any immunities the parties or their officers or employees may possess,nor shall any portion of
this Cooperation Agreement be deemed to have created a duty of care which did not previously exist with
respect to any person not a party to this Cooperation Agreement.
6.No Third-Party Beneficiary Enforcement.It is expressly understood and agreed that the
enforcement of the terms and conditions of this Cooperation Agreement,and all rights of action relating to
such enforcement,shall be strictly reserved to the undersigned parties and nothing in this Cooperation
Agreement shall give or allow any claim or right of action whatsoever by any other person not included in
this Cooperation Agreement.It is the express intention of the undersigned parties that any entity other than
the undersigned parties receiving services or benefits under this Cooperation Agreement shall be an
incidental beneficiary only.
Signed by the parties,as dated below.
WELD OPIOID REGIONAL COUNCIL:
By: �c�Lrc..`._ Date: --t>eLC— l h 2. 241
Robert McDonald,Chair
RECIPIENT:WELD COUNTY DEPARTMENT��// OF PUBLIC HEALTH AND ENVIRONMENT
ATTEST: ,, ) ..1��,%,9o•4. BOARD OF COUNTY COMMISSIONERS
Weld County CI rk to thO1/ QOY1
B oard W 5 OUNTY,COL DO
tor
BY:
e uty Clerk to the Board I'"'" L.B/k,Chair JAN 0 6 2025
EL •
ikdr
44
Z075rOOZ-4
EXHIBIT B
STATEMENT OF WORK
To Cooperation Agreement for Payment of Opioid Settlement Funds
These provisions are to be read and interpreted in conjunction with the provisions of the agreement specified above.
I. Entity(Recipient)Name:Weld County Department of Public Health and Environment
II. Term:January 1,20_5_—December 31,2025_
III. Recipient's Total Allocation for ALL Approved Uses:$112,000.00
IV. Project Description:Weld Region 3 Opioid Abatement Council Administration&Distribution of Weld's Regional
Share of National Opioid Settlement Funds
V. Approved Purposes:can be found at https://nationalopioidsettlement.com/wp-content/uploads/2023/02/
TEVA-Exhibit-E.pdf
VI. Definitions:
COAC—Colorado Opioid Abatement Council
WR3—Weld Opioid Regional Council,Region 3
Allocation—Recipient's share of Opioid funds
Recipient—Agency receiving funding
VII.Work Plan
Approved Purpose#1:J.4 Provide resources to staff government oversight and management of opioid abatement programs
Primary Activity#1 Recipient shall
and Budgeted Have one employee to coordinate WR3 activities and meetings throughout the course of the
Allocation year($99,000.00)
Primary Activity#2 Recipient shall
and Budgeted
Allocation
Primary Activity#3 Recipient shall
and Budgeted
Allocation
Approved Purpose#2:G.PREVENT MISUSE OF OPIOIDS(3,7,8)
Primary Activity#1 Recipient shall
and Budgeted When not providing WR3 support,employee shall engage in evidence supported
Allocation prevention-related activities,including education on medication storage and disposal.These
will take place at schools and community organizations.
Primary Activity#2 Recipient shall
and Budgeted Create evidence-based and evidence-informed materials focused on prevention in the
Allocation community.These will include bilingual promotional and outreach materials that include
mindful use of Rx opioids,harm reduction strategies,and discouraging use for non-users.
Page 1 of 2
EXHIBIT B
Primary Activity#3 Recipient shall
and Budgeted
Allocation
Approved Purpose#3:H.PREVENT OVERDOSE DEATHS AND OTHER HARMS(HARM REDUCTION):1
Primary Activity#1 Recipient shall
and Budgeted Purchase naloxone,distribute it free of charge,and subsequently increase the availability of
Allocation Naloxone at community events and in the Weld County Department of Public Health and
Environment(WCDPHE)clinic.($10,000.00)
Primary Activity#2 Recipient shall
and Budgeted
Allocation
Primary Activity#3 Recipient shall
and Budgeted
Allocation
The primary goal is the success of the WR3 council,with meetings,grant distribution,and
Expected Results of administrative tasks taking place.
Activity(s) Secondary is changes in knowledge,attitudes,and behaviors surrounding substance use in the
community where outreach takes nlace.
1.Number of WR3 meetings held
Measurement of 2.Grants distributed through WR3
Expected Results 3.Individuals reached with prevention-related outreach
4.Units of Naloxone distributed
Completion
Date
Deliverables 1.The Recipient shall submit electronically to the Chair and Fiscal No later than
Agent twice per year distribution requests and financial January 15 and July
information documenting the expenditures and outcomes 15.
related to the distribution requests.
2.The Recipient shall submit electronically to the Chair an annual No later than fifteen
report,or other periodic reports,as required by the COAC. (15)days following
the end of funding
term or thirty(30)
days following
request by Chair for
unanticipated
periodic reports.
Page 2 of 2
Exhibit E
List of Opioid Remediation Uses
Schedule A
Core Strategies
Settling States and Exhibit G Participants may choose from among the abatement strategies
listed in Schedule B.However,priority may be given to the following core abatement strategies
("Core Strategies"))
A. NALOXONE OR OTHER FDA-APPROVED DRUG TO
REVERSE OPIOID OVERDOSES
1. Expand training for first responders,schools,
community support groups and families;and
2. Increase distribution to individuals who are
uninsured or whose insurance does not cover the needed
service.
B. MEDICATION-ASSISTED TREATMENT("MAT')
DISTRIBUTION AND OTHER OPIOID-RELATED
TREATMENT
1. Increase distribution of MAT to individuals who are
uninsured or whose insurance does not cover the needed
service;
2. Provide education to school-based and youth-focused
programs that discourage or prevent misuse;
3. Provide MAT education and awareness training to
healthcare providers,EMTs,law enforcement,and other
first responders;and
4. Provide treatment and recovery support services such as
residential and inpatient treatment,intensive outpatient
treatment,outpatient therapy or counseling,and recovery
housing that allow or integrate medication and with other
support services.
'As used in this Schedule A,words like"expand,""fund,""provide"or the like shall not indicate a preference for
new or existing programs.
E-1
C. PREGNANT&POSTPARTUM WOMEN
1. Expand Screening,Brief Intervention,and Referral to
Treatment("SBIRT')services to non-Medicaid eligible or
uninsured pregnant women;
2. Expand comprehensive evidence-based treatment and
recovery services,including MAT,for women with co-
occurring Opioid Use Disorder("OUD")and other
Substance Use Disorder("SUD")/Mental Health disorders
for uninsured individuals for up to 12 months postpartum;
and
3. Provide comprehensive wrap-around services to individuals
with OUD,including housing,transportation,job
placement/training,and childcare.
D. EXPANDING TREATMENT FOR NEONATAL
ABSTINENCE SYNDROME("NAS'')
1. Expand comprehensive evidence-based and recovery
support for NAS babies;
2. Expand services for better continuum of care with infant-
need dyad;and
3. Expand long-term treatment and services for medical
monitoring of NAS babies and their families.
E. EXPANSION OF WARM HAND-OFF PROGRAMS AND
RECOVERY SERVICES
1. Expand services such as navigators and on-call teams to
begin MAT in hospital emergency departments;
2. Expand warm hand-off services to transition to recovery
services;
3. Broaden scope of recovery services to include co-occurring
SUD or mental health conditions;
4. Provide comprehensive wrap-around services to individuals
in recovery,including housing,transportation,job
placement/training,and childcare;and
5. Hire additional social workers or other behavioral health
workers to facilitate expansions above.
E-2
F. TREATMENT FOR INCARCERATED POPULATION
1. Provide evidence-based treatment and recovery support,
including MAT for persons with OUD and co-occurring
SUD/MH disorders within and transitioning out of the
criminal justice system;and
2. Increase funding for jails to provide treatment to inmates
with OUD.
G. PREVENTION PROGRAMS
1. Funding for media campaigns to prevent opioid use(similar to
the FDA's"Real Cost"campaign to prevent youth from
misusing tobacco);
2. Funding for evidence-based prevention programs in schools;
3. Funding for medical provider education and outreach regarding
best prescribing practices for opioids consistent with CDC
guidelines,including providers at hospitals(academic
detailing);
4. Funding for community drug disposal programs;and
5. Funding and training for first responders to participate in pre-
arrest diversion programs,post-overdose response teams,or
similar strategies that connect at-risk individuals to behavioral
health services and supports.
H. EXPANDING SYRINGE SERVICE PROGRAMS
1. Provide comprehensive syringe services programs with
more wrap-around services,including linkage to OUD
treatment,access to sterile syringes and linkage to care and
treatment of infectious diseases.
I. EVIDENCE-BASED DATA COLLECTION AND
RESEARCH ANALYZING THE EFFECTIVENESS OF THE
ABATEMENT STRATEGIES WITHIN THE STATE
E-3
Schedule B
Approved Uses
Support treatment of Opioid Use Disorder(OUD)and any co-occurring Substance Use Disorder
or Mental Health(SUD/MH)conditions through evidence-based or evidence-informed programs
or strategies that may include,but are not limited to,the following:
PART ONE:TREATMENT
A.TREAT OPIOID USE DISORDER(OUD)
Support treatment of Opioid Use Disorder("OUD")and any co-occurring Substance Use
Disorder or Mental Health("SUD/MH")conditions through evidence-based or evidence-
informed programs or strategies that may include,but are not limited to,those that:2
1. Expand availability of treatment for OUD and any co-occurring SUD/MH conditions,
including all forms of Medication-Assisted Treatment("MAT')approved by the U.S.
Food and Drug Administration.
2. Support and reimburse evidence-based services that adhere to the American Society
of Addiction Medicine("ASAM")continuum of care for OUD and any co-occurring
SUD/MH conditions.
3. Expand telehealth to increase access to treatment for OUD and any co-occurring
SUD/MH conditions,including MAT,as well as counseling,psychiatric support,and
other treatment and recovery support services.
4. Improve oversight of Opioid Treatment Programs("OTPs")to assure evidence-based
or evidence-informed practices such as adequate methadone dosing and low threshold
approaches to treatment.
5. Support mobile intervention,treatment,and recovery services,offered by qualified
professionals and service providers,such as peer recovery coaches,for persons with
OUD and any co-occurring SUD/MH conditions and for persons who have
experienced an opioid overdose.
6. Provide treatment of trauma for individuals with OUD(e.g.,violence,sexual assault,
human trafficking,or adverse childhood experiences)and family members(e.g.,
surviving family members after an overdose or overdose fatality),and training of
health care personnel to identify and address such trauma.
2 As used in this Schedule B,words like"expand,""fund,""provide"or the like shall not indicate a preference for
new or existing programs.
E-4
7. Support evidence-based withdrawal management services for people with OUD and
any co-occurring mental health conditions.
8. Provide training on MAT for health care providers,first responders,students,or other
supporting professionals,such as peer recovery coaches or recovery outreach
specialists,including telementoring to assist community-based providers in rural or
underserved areas.
9. Support workforce development for addiction professionals who work with persons
with OUD and any co-occurring SUD/MH conditions.
10.Offer fellowships for addiction medicine specialists for direct patient care,instructors,
and clinical research for treatments.
11.Offer scholarships and supports for behavioral health practitioners or workers
involved in addressing OUD and any co-occurring SUD/MH or mental health
conditions,including,but not limited to,training,scholarships,fellowships,loan
repayment programs,or other incentives for providers to work in rural or underserved
areas.
12.Provide funding and training for clinicians to obtain a waiver under the federal Drug
Addiction Treatment Act of 2000("DATA 2000")to prescribe MAT for OUD,and
provide technical assistance and professional support to clinicians who have obtained
a DATA 2000 waiver.
13.Disseminate web-based training curricula,such as the American Academy of
Addiction Psychiatry's Provider Clinical Support Service—Opioids web-based
training curriculum and motivational interviewing.
14.Develop and disseminate new curricula,such as the American Academy of Addiction
Psychiatry's Provider Clinical Support Service for Medication—Assisted Treatment.
B. SUPPORT PEOPLE IN TREATMENT AND RECOVERY
Support people in recovery from OUD and any co-occurring SUD/MH conditions
through evidence-based or evidence-informed programs or strategies that may include,
but are not limited to,the programs or strategies that:
1. Provide comprehensive wrap-around services to individuals with OUD and any co-
occurring SUD/MH conditions,including housing,transportation,education,job
placement,job training,or childcare.
2. Provide the full continuum of care of treatment and recovery services for OUD and
any co-occurring SUD/MH conditions,including supportive housing,peer support
services and counseling,community navigators,case management,and connections
to community-based services.
E-5
3. Provide counseling,peer-support,recovery case management and residential
treatment with access to medications for those who need it to persons with OUD and
any co-occurring SUD/MH conditions.
4. Provide access to housing for people with OUD and any co-occurring SUD/MH
conditions,including supportive housing,recovery housing,housing assistance
programs,training for housing providers,or recovery housing programs that allow or
integrate FDA-approved mediation with other support services.
5. Provide community support services,including social and legal services,to assist in
deinstitutionalizing persons with OUD and any co-occurring SUD/MH conditions.
6. Support or expand peer-recovery centers,which may include support groups,social
events,computer access,or other services for persons with OUD and any co-
occurring SUD/MH conditions.
7. Provide or support transportation to treatment or recovery programs or services for
persons with OUD and any co-occurring SUD/MH conditions.
8. Provide employment training or educational services for persons in treatment for or
recovery from OUD and any co-occurring SUD/MH conditions.
9. Identify successful recovery programs such as physician,pilot,and college recovery
programs,and provide support and technical assistance to increase the number and
capacity of high-quality programs to help those in recovery.
10.Engage non-profits,faith-based communities,and community coalitions to support
people in treatment and recovery and to support family members in their efforts to
support the person with OUD in the family.
11.Provide training and development of procedures for government staff to appropriately
interact and provide social and other services to individuals with or in recovery from
OUD,including reducing stigma.
12.Support stigma reduction efforts regarding treatment and support for persons with
OUD,including reducing the stigma on effective treatment.
13.Create or support culturally appropriate services and programs for persons with OUD
and any co-occurring SUD/MH conditions,including new Americans.
14.Create and/or support recovery high schools.
15.Hire or train behavioral health workers to provide or expand any of the services or
supports listed above.
E-6
C.CONNECT PEOPLE WHO NEED HELP TO THE HELP THEY NEED
(CONNECTIONS TO CARE)
Provide connections to care for people who have—or are at risk of developing—OUD
and any co-occurring SUD/MH conditions through evidence-based or evidence-informed
programs or strategies that may include,but are not limited to,those that:
1. Ensure that health care providers are screening for OUD and other risk factors and
know how to appropriately counsel and treat(or refer if necessary)a patient for OUD
treatment.
2. Fund SBIRT programs to reduce the transition from use to disorders,including
SBIRT services to pregnant women who are uninsured or not eligible for Medicaid.
3. Provide training and long-term implementation of SBIRT in key systems(health,
schools,colleges,criminal justice,and probation),with a focus on youth and young
adults when transition from misuse to opioid disorder is common.
4. Purchase automated versions of SBIRT and support ongoing costs of the technology.
5. Expand services such as navigators and on-call teams to begin MAT in hospital
emergency departments.
6. Provide training for emergency room personnel treating opioid overdose patients on
post-discharge planning,including community referrals for MAT,recovery case
management or support services.
7. Support hospital programs that transition persons with OUD and any co-occurring
SUD/MH conditions,or persons who have experienced an opioid overdose,into
clinically appropriate follow-up care through a bridge clinic or similar approach.
8. Support crisis stabilization centers that serve as an alternative to hospital emergency
departments for persons with OUD and any co-occurring SUD/MH conditions or
persons that have experienced an opioid overdose.
9. Support the work of Emergency Medical Systems,including peer support specialists,
to connect individuals to treatment or other appropriate services following an opioid
overdose or other opioid-related adverse event.
10.Provide funding for peer support specialists or recovery coaches in emergency
departments,detox facilities,recovery centers,recovery housing,or similar settings;
offer services,supports,or connections to care to persons with OUD and any co-
occurring SUD/MH conditions or to persons who have experienced an opioid
overdose.
11.Expand warm hand-off services to transition to recovery services.
E-7
12.Create or support school-based contacts that parents can engage with to seek
immediate treatment services for their child;and support prevention,intervention,
treatment,and recovery programs focused on young people.
13.Develop and support best practices on addressing OUD in the workplace.
14.Support assistance programs for health care providers with OUD.
15.Engage non-profits and the faith community as a system to support outreach for
treatment.
16.Support centralized call centers that provide information and connections to
appropriate services and supports for persons with OUD and any co-occurring
SUD/MH conditions.
D.ADDRESS THE NEEDS OF CRIMINAL JUSTICE-INVOLVED PERSONS
Address the needs of persons with OUD and any co-occurring SUD/MH conditions who
are involved in,are at risk of becoming involved in,or are transitioning out of the
criminal justice system through evidence-based or evidence-informed programs or
strategies that may include,but are not limited to,those that:
1. Support pre-arrest or pre-arraignment diversion and deflection strategies for persons
with OUD and any co-occurring SUD/MH conditions,including established strategies
such as:
1. Self-referral strategies such as the Angel Programs or the Police Assisted
Addiction Recovery Initiative("PAARr");
2. Active outreach strategies such as the Drug Abuse Response Team("DART")
model;
3. "Naloxone Plus"strategies,which work to ensure that individuals who have
received naloxone to reverse the effects of an overdose are then linked to
treatment programs or other appropriate services;
4. Officer prevention strategies,such as the Law Enforcement Assisted
Diversion("LEAD")model;
5. Officer intervention strategies such as the Leon County,Florida Adult Civil
Citation Network or the Chicago Westside Narcotics Diversion to Treatment
Initiative;or
6. Co-responder and/or alternative responder models to address OUD-related
911 calls with greater SUD expertise.
E-8
2. Support pre-trial services that connect individuals with OUD and any co-occurring
SUD/MH conditions to evidence-informed treatment,including MAT,and related
services.
3. Support treatment and recovery courts that provide evidence-based options for
persons with OUD and any co-occurring SUD/MH conditions.
4. Provide evidence-informed treatment,including MAT,recovery support,harm
reduction,or other appropriate services to individuals with OUD and any co-
occurring SUD/MH conditions who are incarcerated in jail or prison.
5. Provide evidence-informed treatment,including MAT,recovery support,harm
reduction,or other appropriate services to individuals with OUD and any co-
occurring SUD/MH conditions who are leaving jail or prison or have recently left jail
or prison,are on probation or parole,are under community corrections supervision,or
are in re-entry programs or facilities.
6. Support critical time interventions("CTP'),particularly for individuals living with
dual-diagnosis OUD/serious mental illness,and services for individuals who face
immediate risks and service needs and risks upon release from correctional settings.
7. Provide training on best practices for addressing the needs of criminal justice-
involved persons with OUD and any co-occurring SUD/MH conditions to law
enforcement,correctional,or judicial personnel or to providers of treatment,recovery,
harm reduction,case management,or other services offered in connection with any of
the strategies described in this section.
E. ADDRESS THE NEEDS OF PREGNANT OR PARENTING WOMEN AND
THEIR FAMILIES,INCLUDING BABIES WITH NEONATAL ABSTINENCE
SYNDROME
Address the needs of pregnant or parenting women with OUD and any co-occurring
SUD/MH conditions,and the needs of their families,including babies with neonatal
abstinence syndrome("NAS"),through evidence-based or evidence-informed programs
or strategies that may include,but are not limited to,those that:
1. Support evidence-based or evidence-informed treatment,including MAT,recovery
services and supports,and prevention services for pregnant women—or women who
could become pregnant—who have OUD and any co-occurring SUD/MH conditions,
and other measures to educate and provide support to families affected by Neonatal
Abstinence Syndrome.
2. Expand comprehensive evidence-based treatment and recovery services,including
MAT,for uninsured women with OUD and any co-occurring SUD/MH conditions for
up to 12 months postpartum.
E-9
3. Provide training for obstetricians or other healthcare personnel who work with
pregnant women and their families regarding treatment of OUD and any co-occurring
SUD/MH conditions.
4. Expand comprehensive evidence-based treatment and recovery support for NAS
babies;expand services for better continuum of care with infant-need dyad;and
expand long-term treatment and services for medical monitoring of NAS babies and
their families.
5. Provide training to health care providers who work with pregnant or parenting women
on best practices for compliance with federal requirements that children born with
NAS get referred to appropriate services and receive a plan of safe care.
6. Provide child and family supports for parenting women with OUD and any co-
occurring SUD/MH conditions.
7. Provide enhanced family support and child care services for parents with OUD and
any co-occurring SUD/MH conditions.
8. Provide enhanced support for children and family members suffering trauma as a
result of addiction in the family;and offer trauma-informed behavioral health
treatment for adverse childhood events.
9. Offer home-based wrap-around services to persons with OUD and any co-occurring
SUD/MH conditions,including,but not limited to,parent skills training.
10.Provide support for Children's Services—Fund additional positions and services,
including supportive housing and other residential services,relating to children being
removed from the home and/or placed in foster care due to custodial opioid use.
PART TWO:PREVENTION
F. PREVENT OVER-PRESCRIBING AND ENSURE APPROPRIATE
PRESCRIBING AND DISPENSING OF OPIOIDS
Support efforts to prevent over-prescribing and ensure appropriate prescribing and
dispensing of opioids through evidence-based or evidence-informed programs or
strategies that may include,but are not limited to,the following:
1. Funding medical provider education and outreach regarding best prescribing practices
for opioids consistent with the Guidelines for Prescribing Opioids for Chronic Pain
from the U.S.Centers for Disease Control and Prevention,including providers at
hospitals(academic detailing).
2. Training for health care providers regarding safe and responsible opioid prescribing,
dosing,and tapering patients off opioids.
3. Continuing Medical Education(CME)on appropriate prescribing of opioids.
E-10
4. Providing Support for non-opioid pain treatment alternatives,including training
providers to offer or refer to multi-modal,evidence-informed treatment of pain.
5. Supporting enhancements or improvements to Prescription Drug Monitoring
Programs("PDMPs"),including,but not limited to,improvements that:
1. Increase the number of prescribers using PDMPs;
2. Improve point-of-care decision-making by increasing the quantity,quality,or
format of data available to prescribers using PDMPs,by improving the
interface that prescribers use to access PDMP data,or both;or
3. Enable states to use PDMP data in support of surveillance or intervention
strategies,including MAT referrals and follow-up for individuals identified
within PDMP data as likely to experience OUD in a manner that complies
with all relevant privacy and security laws and rules.
6. Ensuring PDMPs incorporate available overdose/naloxone deployment data,
including the United States Department of Transportation's Emergency Medical
Technician overdose database in a manner that complies with all relevant privacy and
security laws and rules.
7. Increasing electronic prescribing to prevent diversion or forgery.
8. Educating dispensers on appropriate opioid dispensing.
G.PREVENT MISUSE OF OPIOIDS
Support efforts to discourage or prevent misuse of opioids through evidence-based or
evidence-informed programs or strategies that may include,but are not limited to,the
following:
1. Funding media campaigns to prevent opioid misuse.
2. Corrective advertising or affirmative public education campaigns based on evidence.
3. Public education relating to drug disposal.
4. Drug take-back disposal or destruction programs.
5. Funding community anti-drug coalitions that engage in drug prevention efforts.
6. Supporting community coalitions in implementing evidence-informed prevention,
such as reduced social access and physical access,stigma reduction—including
staffing,educational campaigns,support for people in treatment or recovery,or
training of coalitions in evidence-informed implementation,including the Strategic
Prevention Framework developed by the U.S.Substance Abuse and Mental Health
Services Administration("SAMHSA").
E-11
7. Engaging non-profits and faith-based communities as systems to support prevention.
8. Funding evidence-based prevention programs in schools or evidence-informed school
and community education programs and campaigns for students,families,school
employees,school athletic programs,parent-teacher and student associations,and
others.
9. School-based or youth-focused programs or strategies that have demonstrated
effectiveness in preventing drug misuse and seem likely to be effective in preventing
the uptake and use of opioids.
10.Create or support community-based education or intervention services for families,
youth,and adolescents at risk for OUD and any co-occurring SUD/MH conditions.
11.Support evidence-informed programs or curricula to address mental health needs of
young people who may be at risk of misusing opioids or other drugs,including
emotional modulation and resilience skills.
12.Support greater access to mental health services and supports for young people,
including services and supports provided by school nurses,behavioral health workers
or other school staff,to address mental health needs in young people that(when not
properly addressed)increase the risk of opioid or another drug misuse.
H.PREVENT OVERDOSE DEATHS AND OTHER HARMS(HARM REDUCTION)
Support efforts to prevent or reduce overdose deaths or other opioid-related harms
through evidence-based or evidence-informed programs or strategies that may include,
but are not limited to,the following:
1. Increased availability and distribution of naloxone and other drugs that treat
overdoses for first responders,overdose patients,individuals with OUD and their
friends and family members,schools,community navigators and outreach workers,
persons being released from jail or prison,or other members of the general public.
2. Public health entities providing free naloxone to anyone in the community.
3. Training and education regarding naloxone and other drugs that treat overdoses for
first responders,overdose patients,patients taking opioids,families,schools,
community support groups,and other members of the general public.
4. Enabling school nurses and other school staff to respond to opioid overdoses,and
provide them with naloxone,training,and support.
5. Expanding,improving,or developing data tracking software and applications for
overdoses/naloxone revivals.
6. Public education relating to emergency responses to overdoses.
E-12
7. Public education relating to immunity and Good Samaritan laws.
8. Educating first responders regarding the existence and operation of immunity and
Good Samaritan laws.
9. Syringe service programs and other evidence-informed programs to reduce harms
associated with intravenous drug use,including supplies,staffing,space,peer support
services,referrals to treatment,fentanyl checking,connections to care,and the full
range of harm reduction and treatment services provided by these programs.
10.Expanding access to testing and treatment for infectious diseases such as HIV and
Hepatitis C resulting from intravenous opioid use.
11.Supporting mobile units that offer or provide referrals to harm reduction services,
treatment,recovery supports,health care,or other appropriate services to persons that
use opioids or persons with OUD and any co-occurring SUD/MH conditions.
12.Providing training in harm reduction strategies to health care providers,students,peer
recovery coaches,recovery outreach specialists,or other professionals that provide
care to persons who use opioids or persons with OUD and any co-occurring SUD/MH
conditions.
13.Supporting screening for fentanyl in routine clinical toxicology testing.
PART THREE:OTHER STRATEGIES
I. FIRST RESPONDERS
In addition to items in section C,D and H relating to first responders,support the
following:
1. Education of law enforcement or other first responders regarding appropriate
practices and precautions when dealing with fentanyl or other drugs.
2. Provision of wellness and support services for first responders and others who
experience secondary trauma associated with opioid-related emergency events.
J. LEADERSHIP,PLANNING AND COORDINATION
Support efforts to provide leadership,planning,coordination,facilitations,training and
technical assistance to abate the opioid epidemic through activities,programs,or
strategies that may include,but are not limited to,the following:
1. Statewide,regional,local or community regional planning to identify root causes of
addiction and overdose,goals for reducing harms related to the opioid epidemic,and
areas and populations with the greatest needs for treatment intervention services,and
E-13
to support training and technical assistance and other strategies to abate the opioid
epidemic described in this opioid abatement strategy list.
2. A dashboard to(a)share reports,recommendations,or plans to spend opioid
settlement funds;(b)to show how opioid settlement funds have been spent;(c)to
report program or strategy outcomes;or(d)to track,share or visualize key opioid-or
health-related indicators and supports as identified through collaborative statewide,
regional,local or community processes.
3. Invest in infrastructure or staffing at government or not-for-profit agencies to support
collaborative,cross-system coordination with the purpose of preventing
overprescribing,opioid misuse,or opioid overdoses,treating those with OUD and any
co-occurring SUD/MH conditions,supporting them in treatment or recovery,
connecting them to care,or implementing other strategies to abate the opioid
epidemic described in this opioid abatement strategy list.
4. Provide resources to staff government oversight and management of opioid abatement
programs.
K.TRAINING
In addition to the training referred to throughout this document,support training to abate
the opioid epidemic through activities,programs,or strategies that may include,but are
not limited to,those that:
1. Provide funding for staff training or networking programs and services to improve the
capability of government,community,and not-for-profit entities to abate the opioid
crisis.
2. Support infrastructure and staffing for collaborative cross-system coordination to
prevent opioid misuse,prevent overdoses,and treat those with OUD and any co-
occurring SUD/MH conditions,or implement other strategies to abate the opioid
epidemic described in this opioid abatement strategy list(e.g.,health care,primary
care,pharmacies,PDMPs,etc.).
L. RESEARCH
Support opioid abatement research that may include,but is not limited to,the following:
1. Monitoring,surveillance,data collection and evaluation of programs and strategies
described in this opioid abatement strategy list.
2. Research non-opioid treatment of chronic pain.
3. Research on improved service delivery for modalities such as SBIRT that
demonstrate promising but mixed results in populations vulnerable to opioid use
disorders.
E-14
4. Research on novel harm reduction and prevention efforts such as the provision of
fentanyl test strips.
5. Research on innovative supply-side enforcement efforts such as improved detection
of mail-based delivery of synthetic opioids.
6. Expanded research on swift/certain/fair models to reduce and deter opioid misuse
within criminal justice populations that build upon promising approaches used to
address other substances(e.g.,Hawaii HOPE and Dakota 24/7).
7. Epidemiological surveillance of OUD-related behaviors in critical populations,
including individuals entering the criminal justice system,including,but not limited
to approaches modeled on the Arrestee Drug Abuse Monitoring("ADAM")system.
8. Qualitative and quantitative research regarding public health risks and harm reduction
opportunities within illicit drug markets,including surveys of market participants
who sell or distribute illicit opioids.
9. Geospatial analysis of access barriers to MAT and their association with treatment
engagement and treatment outcomes.
E-15
Contract Form
Entity Information
Entity Name* Entity ID* ❑New Entity?
WELD OPIOID REGIONAL COUNCIL @00047970
Contract Name* Contract ID Parent Contract ID
COOPERATIVE AGREEMENT FOR PAYMENT OF OPIOID 8989
SETTLEMENT FUNDS Contract Lead* Requires Board Approval
Contract Status BFRITZ YES
CTB REVIEW
Contract Lead Email Department Project#
bfritz@weld.gov;Health-
Contracts@weld.gov
Contract Description*
COOPERATIVE AGREEMENT FOR PAYMENT OF OPIOID SETTLEMENT FUNDS
Contract Description 2
Contract Type* Department Requested BOCC Agenda Due Date
AGREEMENT HEALTH Date* 01/02/2025
01/06/2025
Amount* Department Email
$1 13,000.00 CM-Health@weld.gov Will a work session with BOCC be required?*
NO
Renewable* Department Head Email
NO CM-Health- Does Contract require Purchasing Dept.to be
DeptHead@weld.gov included?
Automatic Renewal
County Attorney
Grant GENERAL COUNTY
ATTORNEY EMAIL
IGA County Attorney Email
CM-
COUNTYATTORNEY@WEL
D.GOV
If this is a renewal enter previous Contract ID
If this is part of a MSA enter MSA Contract ID
Note:the Previous Contract Number and Master Services Agreement Number should be left blank if those contracts
are not in OnBase
Contract Dates
Effective Date Review Date* Renewal Date
12/01/2025
Termination Notice Period Committed Delivery Date Expiration Date*
12/31/2025
Contact Information
Contact Info
Contact Name Contact Type Contact Email Contact Phone 1 Contact Phone 2
Purchasing
Purchasing Approver Purchasing Approved Date
Approval Process
Department Head Finance Approver Legal Counsel
JASON CHESSHER CHERYL PATTELLI BYRON HOWELL
DH Approved Date Finance Approved Date Legal Counsel Approved Date
12/26/2024 12/27/2024 12/30/2024
Final Approval
BOCC Approved Tyler Ref#
AG 010625
BOCC Signed Date Originator
BFRITZ
BOCC Agenda Date
01/06/2025
Hello